van Roessel S, van Veldhuisen E, Klompmaker S, et al. - Researchers undertook this international, multicenter, retrospective cohort study to examine the link of adjuvant chemotherapy with overall survival in patients following pancreatic cancer resection and neoadjuvant FOLFIRINOX (folinic acid, fluorouracil, irinotecan, and oxaliplatin) treatment. After applying inclusion and exclusion criteria, a total of 520 patients (median age, 61 years; 279 [53.7%] men) from 31 centers in 19 countries were included in this study. According to findings, improved survival in relation to adjuvant chemotherapy following neoadjuvant FOLFIRINOX and resection of pancreatic cancer was observed only in patients with pathology-confirmed node-positive disease.